Teva VP Ika Abravanel resigns
The President will set up an NPO for brain research led by Dr. Rafi Gidron.
President Shimon Peres announced at the 10th ILSI-Biomed Conference 2011 today that he will set up a non-profit organization to support brain research in Israel, which will be headed by Dr. Rafi Gidron. Gidron, a co-founder of Chromatis Networks, which was sold to Lucent for over $4 billion in 2000, is currently involved in volunteer work and invests in cleantech companies through his firm Precede Technologies Ltd.
The aim of the proposed NPO will be to shift the emphasis of research in Israel towards brain research through conventions, steering committees, and, most importantly, by raising money. The NPO will identify the most interesting and important subfields in brain research where Israel has the greatest comparative advantage, and raise capital to support basic and applied research in them via a range of research institutes, NPOs, and possibly young commercial companies.
Peres told "Globes", "We intend to replicate our achievements in nanotechnology in neurotechnology, but the scale will be much greater and more impressive."
The president's aides said that Peres helped raise hundreds of millions of dollars for nanotechnology research, and that he could probably do the same for neurotechnology.
Gidron said that two areas would be the focus of research: the human-machine interface and therapies. At ILSI Biomed 2011, Peres and Gidron met top Israeli and foreign brain researchers, as well as Office of the Chief Scientist head of life sciences Ora Dar. They identified several important subjects for action, including early diagnostics for neurological and psychiatric disorders, support and for demonstration for academic ideas, and support for the use of advanced medical computer systems at Israel's hospitals and health funds to collect data and conduct research on brain disorders, including depression, Alzheimer's, Parkinson's disease, autism, strokes, and schizophrenia.
In the coming months, the NPO will convene a steering committee to formulate a road map for operations, after which it will begin raising capital and publish calls for papers for researchers and companies.
The first fruit of this activity is the raising of $10 million for neuron computability - the translation of brain activity for the computer. The money was raised from foreign donors for a special foundation that will finance a joint research team from the Hebrew University of Jerusalem and the Swiss Federal Polytechnic School of Lausanne.
Peres said, "Israel lives on its brain. This is not a one-time thing, it is something renewed constantly and ever more powerfully. We're now embarking on the fourth revolution. The first were the agricultural, industrial, and information revolutions, and now comes the revolution of the brain. This is a problem that Israel devotes itself to solving as quickly as possible and as strongly as possible."
Published by Globes [online], Israel business news - www.globes-online.com - on May 23, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011
You comment was recieved and soon will be published.
Load more comments
Abravanel's is the first senior departure from Teva since Erez Vigodman became CEO.
FDA approves Pluristem cell production facility
Pluristem's Haifa plant can produce 150,000 doses of PLX cells annually.
Desheh: Splitting Teva will not create value
Teva CFO Eyal Desheh says Teva's tight integration means that a split makes no sense.
InsuLine expanding in Europe
24Care will distribute the company's InsuPad product in the Netherlands and Belgium.
Teva launches generic breast cancer, osteoporosis drug
Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million.
BiolineRX raising $21m in Nasdaq secondary offering
The company will use the proceeds to develop leukemia and celiac disease drugs.
MediWound sets terms for $92m Nasdaq IPO
The burns and wounds treatment developer's offering is at a value of $350-370 million.
Opko losses triple
CEO Phillip Frost: From an R&D perspective, all our programs are progressing.
D-Pharm doubles on good interim stroke study results
The Phase IIa trial interim results found the company's drug was safe for cerebral strokes.
Perrigo selling OTC drugs through Amazon
Perrigo: It is also a platform for obtaining good information about consumer behavior.
Teva launches bipolar, schizophrenia treatment
Adasuve is the first orally inhaled medicine for the acute treatment of agitation in schizophrenia and bipolar I disorder.
Perrigo acquires Aspen Global products for $51m
Perrigo bought value-brand OTC products sold in Australia and New Zealand.
Galmed updates $30m Nasdaq IPO prospectus
The liver disease drug developer will issue shares at a company value of $132 million.
Enzymotec shareholders raise $131m in offer to sell
Kibbutz Ma'anit's Galam reportedly sold shares for $46 million.
Compugen raises $63m, Magic $51m
The two companies held secondary offerings on Nasdaq on the basis of shelf prospectuses.
If Rose Fostanes played basketball
Reforms in regulations for foreign caregivers are welcome, but don't go far enough.
Private treatment kills public healthcare
If the German Committee validates private healthcare, it will be the last nail in public healthcare's coffin, argues Prof Dani Filc.
Reducing the number of polyps that colonoscopies miss
EndoChoice's Israel development center has devised an endoscope with a 330-degree arc.
Neopharm moves into orphan drugs
The company, better known for marketing others' products, has been quietly building up its innovative capacity, as VP Tal Fuhrer relates..
Merck Serono Israel incubator nurtures early stage projects
Merck Germany head of pharmaceuticals Dr. Stefan Oschmann says R&D is enjoying a renaissance at big pharma companies.
Israeli biomed cos bring in US CEOs
"Globes" speaks to 3 US CEOs appointed to boost marketing at TASE traded medical device companies.
Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.
Restructuring can help Teva's Copaxone woes
Avishai Ovadia argues that Teva can offset falling Copaxone sales by reducing overall company costs.
Enabling diabetes patients to sleep soundly
Excess insulin levels can be fatal when they occur at night. NightSense aims to remove the fear.